Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR ...

Merck Animal Health is investing $895 million in its Kansas facility. Novo Nordisk anticipates Wegovy sales recovery ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention. Helen Coffey speaks to the dentists warning that jabs could have a worrying im ...

Ooops... Something went wrong while loading this page.

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Current health news covers major investments by Merck Animal Health and Gilead Sciences in the U.S., regulatory decisions ...

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

WeightWatchers isn’t the only company to feel the disruptive power of the weight loss drugs. London-listed but Irish-based ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

We all snore at some stage in our life, but what is snoring and what can you do if you have obstructive sleep apnea?

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...